Core Insights - Coeptis Therapeutics Holdings, Inc. has rebranded to COEPTIS, indicating a strategic shift to expand beyond biopharmaceuticals into technology-driven sectors [1][3] - The establishment of a new Technology Division aims to enhance operational capabilities and maximize shareholder value, highlighted by the acquisition of the NexGenAI Affiliates Network platform [1][6] - The integration of NexGenAI's tools will empower COEPTIS to address marketing challenges with AI-driven precision and efficiency, focusing on automation and workflow optimization [2][6] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company dedicated to developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [4][5] - The company's therapeutic portfolio includes assets licensed from Deverra Therapeutics, featuring an allogeneic cellular immunotherapy platform and clinical-stage NK cell therapy technology [5] - COEPTIS is committed to advancing treatment paradigms and improving patient outcomes through cutting-edge research and development efforts [4][5] Technology Division - The newly established Technology Division focuses on enhancing operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation [6] - This division aims to optimize business processes and improve overall efficiency, positioning COEPTIS as a self-sustaining entity for long-term growth and profitability [3][6]

Core Insights - Coeptis Therapeutics is expanding its technological initiatives by integrating artificial intelligence and blockchain solutions to enhance operational efficiency and strategic growth [1][2][3] Company Overview - Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [4][5] - The company operates through subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. [4] Technological Advancements - The successful launch of the Technology Division has introduced transformative AI capabilities, significantly improving operational efficiency and customer engagement [2][6] - The Technology Division includes AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group [6] Strategic Vision - The integration of blockchain technology into the Technology Division reflects Coeptis's commitment to adapting to emerging trends and leveraging new market opportunities for enhanced value creation [3] - The company aims to remain at the forefront of technological developments while exploring synergies that benefit customers and shareholders [3]

Core Insights - Coeptis Therapeutics has secured five new clients with a total contract value of $1.7 million, indicating strong market interest in its NexGenAI Affiliates Network platform [1][2] - The company anticipates a revenue stream of $450,000 from Managed Services Agreements valued at $1.25 million, highlighting the immediate market opportunity for its AI-driven marketing solutions [2] - The CEO of Coeptis expressed optimism about the early uptake of the NexGenAI platform, emphasizing its potential to enhance customer engagement and marketing strategies [3][5] Company Overview - Coeptis Therapeutics is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [5] - The company’s product portfolio includes assets licensed from Deverra Therapeutics and a universal CAR T technology licensed from the University of Pittsburgh [5] Technology and Innovation - The NexGenAI Affiliates Network is designed to revolutionize marketing and business operations through AI-driven marketing software, robotic process automation, and data analytics [7] - Upcoming features of the NexGenAI platform include an AI Dialer Service, AI SMS Service, and advanced RPA Assistance, aimed at enhancing communication and operational efficiency [8] Market Trends - The integration of AI in marketing is transforming the industry by enabling businesses to personalize campaigns, optimize in real-time, and gain insights into consumer behavior [4] - As AI technology evolves, it is expected to play a crucial role in shaping various sectors and driving advancements in business practices [4]

Core Viewpoint - Coeptis Therapeutics Holdings, Inc. will implement a 1-for-20 reverse stock split to comply with Nasdaq Capital Market listing requirements, following approval from its board and stockholders [1][4][5] Group 1: Reverse Stock Split Details - The reverse stock split will convert every 20 shares of the Company's common stock into one share, with no fractional shares issued; any resulting fractions will be rounded up to the next whole number [3] - The effective date for the reverse stock split is December 31, 2024, marking the first day of trading on a post-split basis [2][3] Group 2: Purpose and Approval - The reverse stock split aims to help the Company meet the minimum bid price requirement of $1.00 per share as mandated by Nasdaq rules [4] - The reverse split was approved at the Company's Annual Stockholder's Meeting on December 18, 2024, after which the board established the split ratio [5] Group 3: Company Overview - Coeptis Therapeutics is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [7] - The Company’s product portfolio includes assets licensed from Deverra Therapeutics and a universal CAR technology licensed from the University of Pittsburgh [7]

Coeptis Aims to Bring AI Innovation in Biotechnology and TechnologyWEXFORD, Pa., Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company specializing in innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, proudly announces the completion of its acquisition of the NexGenAI Affiliates Network platform alongside the official launch of Coeptis Technologies. This new division is strategically aimed a ...

Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a Risk Mitigation Software Company with 10,000 customers in over 100 countries, Expanding into the Booming Data Security Sector following the upcoming acquisition of NexGenAI Affiliates NetworkWEXFORD, Pa., Dec. 12, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious dis ...

The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for GrowthWEXFORD, Pa. , Dec. 3, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce the execution of a Binding Letter of Intent for the acquisition of NexGenAI Affiliates Netw ...

Table of Contents Title of each class Trading Symbol(s) Name of exchange on which registered Common Stock, par value $0.0001 per share COEP Nasdaq Capital Market Warrants, each whole warrant exercisable for onehalf of one share of Common Stock for $11.50 per whole share COEPW Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September ...

Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of diseaseDVX201, the first allogeneic NK cell therapy derived from pooled donor cord blood CD34+ cells, was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxicities WEXFORD, Pa., Nov. 7, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" ...

WEXFORD, Pa., Oct. 24, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced the expansion of its license agreement with Deverra Therapeutics Inc. ("Deverra"), broadening the potential applications of its allogeneic natural killer (NK) cell technology. This expansion includes the use of unmodified NK cells in treating viral ...